Patent intelligence · US
US 9694111
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
Patent details — US 9694111
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 4, 2017
- Expiration
- Jun 29, 2037
- Applicant
- Lutonix, Inc.
- Claims
- 20
- CPC classes
- A61K, A61K31/337, A61K31/436
Quick answer
US 9694111 (Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent) is held by Lutonix, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Lutonix, Inc.
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/337, A61K31/436
More from Lutonix, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12383733
Iontophoresis-based patch type medicine absorption device
granted -
US 12365879
Synthetic chimeric poxviruses
granted -
US 12304901
Selective ligands for tau aggregates
granted -
US 12156897
Magnesium-containing oxytocin formulations and methods of use
granted -
US 12156864
Analogs of cyclobenzaprine and amitryptilene
granted -
US 12097183
Pharmaceutical composition for treating migraine
granted -
US 12090139
Formulations comprising triptan compounds
granted -
US 11998516
Methods and compositions for treating depression using cyclobenzaprine
granted
Frequently asked questions
What is US patent 9694111?
US 9694111 (Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent) is held by Lutonix, Inc.. Status: granted. Granted Jul 4, 2017. Expires Jun 29, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9694111?
Lutonix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 86 pharmaceutical patents for this assignee.
When does US 9694111 expire?
Our index shows an expiration date of Jun 29, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.